SCUEL — Japan healthcare data

HomeTherapeutic areas › Antibiotics acting mainly on Gram-positive bacteria

Japan market screening · Therapeutic class

Antibiotics acting mainly on Gram-positive bacteria in Japan

主としてグラム陽性菌に作用するもの · Japan Standard Commodity Classification

10 molecules in this class are marketed in Japan across 53 products. 6 of those products are not shipping normally today — 11.3% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.

10Molecules
53Marketed products
6Products constrained

Molecules in this class

Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.

MoleculeProducts CompaniesConstrained Supply mix
Vancomycin Hydrochlorideバンコマイシン塩酸塩1471
Arbekacin Sulfateアルベカシン硫酸塩123
Teicoplaninテイコプラニン963
Lincomycin Hydrochloride Hydrateリンコマイシン塩酸塩水和物72
Daptomycinダプトマイシン33
Benzylpenicillin Benzathine Hydrateベンジルペニシリンベンザチン水和物212
Benzylpenicillin Potassiumベンジルペニシリンカリウム21
Clindamycin Hydrochlorideクリンダマイシン塩酸塩21
Fidaxomicinフィダキソマイシン11
Mupirocin Calcium Hydrateムピロシンカルシウム水和物11
Normal supply Limited supply Supply suspended

How to read this

Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.

Screening this area in Japan?

Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.

Send an enquiry

Our Database Division replies in English within three business days (Japan time).